// App-Quantinova.ai

P2-15-06 : BRCA1/2 status, treatment patterns and safety outcomes in HER2- advanced breast cancer (ABC): Results from a US real-world study

Researchers

Presenter

  • Michael P. Lux

Principal Investigators

  • Katie Lewis

  • Alex Rider

  • Alexander Niyazov

Medical Centers

  • Kooperatives Brustzentrum Paderborn, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Frauen- und Kinderklinik St. Louise, Paderborn, Germany

  • Adelphi Real World, Cheshire, United Kingdom

  • Pfizer Inc, New York, NY

Locations

  • Germany

  • United Kingdom

  • United States

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • erb-b2 receptor tyrosine kinase 2

  • BRCA mutation

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved